Catalog No.: PC-20714Not For Human Use, Lab Use Only.
ME-143 (NV-143) is a second-generation tumor-specific NADH oxidase inhibitor, binds to purified recombinant ENOX2 with Kd value of 43 nM, shows broad activity against human cancers in vitro and in vivo.
ME-143 (NV-143) is a second-generation tumor-specific NADH oxidase inhibitor, binds to purified recombinant ENOX2 with Kd value of 43 nM, shows broad activity against human cancers in vitro and in vivo.
ME-143 is a more than 10-fold potent inhibitor of DLD1 proliferation than genistein at 3.125 μM.
ME-143 significantly reduced WNT throughput by 65-75% in both the RKO and DLD1 cell lines.
ME-143 alone and in combination with 5FU and oxaliplatin effectively inhibits the WNT/β-catenin pathway in colorectal cancer cells of diverse genetic background.
Physicochemical Properties
M.Wt
334.37
Formula
C21H18O4
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
4,4'-(7-hydroxychromane-3,4-diyl)diphenol
References
1. Morré DJ, et al. Oncol Res. 2014;22(1):1-12.
2. Pintova S, et al. Anticancer Res. 2017 Apr;37(4):1647-1653.
